scholarly journals Reduced Grating Acuity Associated with Retinal Toxicity in Children with Infantile Spasms on Vigabatrin Therapy

2009 ◽  
Vol 50 (8) ◽  
pp. 4011 ◽  
Author(s):  
Sivan Durbin ◽  
Giuseppe Mirabella ◽  
J. Raymond Buncic ◽  
Carol A. Westall
Keyword(s):  
Retinal Toxicity ◽  
Infantile Spasms ◽  
Grating Acuity

Vigabatrin in the Treatment of Infantile Spasms

US Neurology ◽  
2010 ◽  
Vol 05 (02) ◽  
pp. 82
Author(s):  
Susana E Camposano ◽  
Elizabeth A Thiele ◽  
◽  
Keyword(s):  
Risk Factors ◽  
Effective Treatment ◽  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Side Effect ◽  
Visual Fields ◽  
Retinal Toxicity ◽  
Infantile Spasms ◽  
Duration Of Treatment ◽  
Drug Of Choice

Vigabatrin (VGB) is an effective treatment of infantile spasms (IS) that controls spasms of all etiologies in about 50% of patients when used asmonotherapy. In tuberous sclerosis complex, VGB controls spasms in up to 95% of patients and should be used as the drug of choice. HigherVGB doses correlate with shorter times to response and higher response rates. Its most serious side effect is retinal toxicity characterized byirreversible bilateral concentric constriction of the visual fields (BCCVF). Maximum VGB dose, total VGB dose, and duration of VGB treatmentconstitute risk factors for BCCVF. In each particular patient, dose and duration of treatment should be kept at a minimum, while ensuringeffectiveness and preventing relapse. Every effort should be made to evaluate retinal function, even though it may require specializedophthalmological services. The addition of this new US Food and Drug Administration (FDA)-approved drug as an alternative in the treatmentof IS represents a major contribution to an armamentarium that contains only one other treatment.

Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex

2018 ◽  
Vol 33 (8) ◽  
pp. 519-524 ◽  
Author(s):  
Emma A. van der Poest Clement ◽  
Mustafa Sahin ◽  
Jurriaan M. Peters
Keyword(s):  
Tuberous Sclerosis ◽  
Tuberous Sclerosis Complex ◽  
Retinal Toxicity ◽  
Infantile Spasms ◽  
Line Treatment ◽  
First Line ◽  
Epileptic Spasms ◽  
Treatment Onset ◽  
First Line Treatment

Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known. We retrospectively reviewed 201 children with tuberous sclerosis complex, and identified 21 children older than 1 year started on vigabatrin for any indication and with sufficient follow-up data. The indication for vigabatrin was epileptic spasms (n = 13), tonic seizures (n = 5), both (n = 2), and status epilepticus (n = 1). Mean age of treatment onset was 4.0 years (range 1.1-18.3). All but 1 patient had a reduction in seizures. Ten patients became seizure free and 4 had an improvement of >90%. In 9 patients, vigabatrin was tapered successfully after 8 to 33 months. Side effects reported included rash (n = 1) and behavioral decline (n = 1). No retinal toxicity was detected in 14 of 21 patients with adequate ophthalmologic surveillance data. In conclusion, vigabatrin may be an effective treatment for epileptic spasms and tonic seizures beyond the infantile age.

Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort studyAuthor Response

Neurology ◽  
2015 ◽  
Vol 85 (7) ◽  
pp. 655.2-656 ◽  
Author(s):  
James D. Akula ◽  
Carol A. Westall ◽  
Thomas Wright
Keyword(s):  
Retinal Toxicity ◽  
Infantile Spasms ◽  
Observational Cohort

scholarly journals Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study

Neurology ◽  
2014 ◽  
Vol 83 (24) ◽  
pp. 2262-2268 ◽  
Author(s):  
C. A. Westall ◽  
T. Wright ◽  
F. Cortese ◽  
A. Kumarappah ◽  
O. C. Snead ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retinal Toxicity ◽  
Infantile Spasms ◽  
Observational Cohort Study ◽  
Observational Cohort
Sign in / Sign up

Export Citation Format

Share Document